routine matter that will only affect air traffic procedures and air navigation it is certified that this rule will not have significant economic impact on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 71

Airspace, Incorporation by reference, Navigation (air).

Adoption of the Amendment

In consideration of the foregoing, the Federal Aviation Administration amends 14 CFR part 71 as follows:

PART 71—[AMENDED]

1. The authority citation for 14 CFR Part 71 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40103, 40113, 40120; EO 10854, 24 FR 9565, 3 CFR, 1959–1963 Comp., p. 389; 14 CFR 11.69.

§ 71.1 [Amended]

2. The incorporation by reference in 14 CFR 71.1 of Federal Aviation Administration Order 7400.9D, Airspace Designation and Reporting Points, dated September 4, 1996, and effective September 16, 1996, is amended as follows:

Paragraph 6005 Class E airspace areas extending upward from 700 feet or more above the surface of the earth.

* * * * *

AEA NY AEA E5 Dunkirk, NY [Revised]

Chautauqua County/Dunkirk Airport, NY
(Lat. 42°29′36″ N., long. 79°16′19″ W.)
Angola Airport, NY
(Lat. 42°39′37″ N., long. 78°59′28″ W.)
Dunkirk VORTAC, NY
(Lat. 42°29′26″ N., long. 79°16′27″ W.)

That airspace extending upward from 700 feet above the surface within a 6.6-mile radius of Chautauqua County/Dunkirk Airport and within 11.8-mile radius of the airport extending clockwise from a 022° to a 264° bearing from the airport and within a 6.3 mile radius of the Angola Airport and within 5.3 miles northwest of 051° radial from the Dunkirk VORTAC and within 5.3 miles northwest of the 231° radial from the VORTAC extending from the 6.3-mile radius to 9.9 miles southwest of the VORTAC.

* * * * *

Issued in Jamaica, New York on February 21, 1997.

James K. Buckles,

Acting Manager, Air Traffic Division, Eastern Region.

[FR Doc. 97–5436 Filed 3–4–97; 8:45 am]

BILLING CODE 4910–13–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 558

New Animal Drugs for Use in Animal Feeds; Laidlomycin Propionate Potassium

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Hoffmann-LaRoche, Inc. The supplemental NADA provides for use of dry laidlomycin propionate potassium Type A articles for making liquid Type B medicated feeds used to make dry Type C medicated feeds. The Type C feeds are for cattle fed in confinement for slaughter for increased rate of weight gain and improved feed efficiency.

EFFECTIVE DATE: March 5, 1977.

FOR FURTHER INFORMATION CONTACT: Russell G. Arnold, Center for Veterinary Medicine (HFV–142), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1674.

SUPPLEMENTARY INFORMATION: Hoffmann-LaRoche, Inc., Nutley, NJ 07110, filed supplemental NADA 141–025, which provides for use of Cattylyst® 50 (50 grams (g) per pound laidlomycin propionate potassium) dry Type A articles to make liquid, 100 to 2,000 g per ton (g/t) laidlomycin propionate potassium Type B feeds, used to make dry, 5 to 10 g/t laidlomycin propionate potassium Type C feeds. The Type C feeds are for cattle fed in confinement for slaughter for increased rate of weight gain and improved feed efficiency. The supplemental NADA is approved as of March 5, 1997, and § 558.305 (21 CFR 558.305) is amended to reflect the approval.

In addition, certain mixing directions for liquid feeds are required for use of laidlomycin propionate potassium liquid Type B feeds to make Type C feeds. Those directions had not been previously codified in the regulation. At this time, existing § 558.305(b) is redesignated as § 558.305(d) and new paragraph (b) is added to include those directions. New § 558.305(c) is established and reserved for future use.

The supplement is for a new formulation of an approved product used to make another approved product. Approval does not affect the basis of approval or the conditions of use of the currently approved application. No additional safety or effectiveness data are required. Therefore, a freedom of information summary is not required. A summary of safety and effectiveness data and information submitted to support approval of the original application may be seen in the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday.

Under section 512(c)(2)(F)(iii) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(iii)), this approval does not qualify for marketing exclusivity because the supplement does not contain substantial evidence of effectiveness of the drugs involved, any studies of animal safety or, in the case of food-producing animals, human food safety studies (other than bioequivalence or residue studies) required for approval and conducted or sponsored by the applicant.

The agency has determined under 21 CFR 25.24(d)(1)(iii) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

List of Subjects in 21 CFR Part 558

Animal drugs, Animal feeds.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 558 is amended as follows:

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

1. The authority citation for 21 CFR part 558 continues to read as follows:

Authority: Secs. 512, 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b, 371).

2. Section 558.305 is amended by redesignating paragraph (b) as paragraph (d), by adding new paragraphs (b) and (c), and by revising the title of redesignated paragraph (d)(3) to read as follows:

§ 558.305 Laidlomycin propionate potassium.

* * * * *

(b) *Special considerations.* (1) Laidlomycin liquid Type B feeds may be manufactured from dry laidlomycin Type A articles. The liquid Type B feeds must have a pH of 6.0 to 8.0, dry matter of 62 to 75 percent, and bear appropriate mixing directions as follows:

(i) For liquid Type B feeds stored in recirculating tank systems: Recirculate immediately prior to use for no less than 10 minutes, moving not less than 1 percent of the tank contents per minute from the bottom of the tank to the top. Recirculate daily as described even when not used.

(ii) For liquid Type B feeds stored in mechanical, air, or other agitation type tank systems: Agitate immediately prior to use for not less than 10 minutes, creating a turbulence at the bottom of the tank that is visible at the top. Agitate daily as described even when not used.

(2) The expiration date for the liquid Type B feed is 21 days after date of manufacture. The expiration date for the dry Type C feed made from the liquid Type B feed is 7 days after date of manufacture.

(c) [Reserved]

(d) * * *

(3) *Additional limitations.* * * *

Dated: February 6, 1997.

Robert C. Livingston,

Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

[FR Doc. 97–5312 Filed 3–4–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

24 CFR Part 203

[Docket No. FR–4032–I–02]

RIN 2502–AG72

Single Family Mortgage Insurance—Loss Mitigation Procedures Suspension of Certain Provisions of Interim Rule

AGENCY: Office of the Assistant Secretary for Housing—Federal Housing Commissioner, HUD.

ACTION: Suspension of certain provisions of interim rule.

SUMMARY: This document suspends, until the date of publication of a final rule, the last sentence in introductory paragraph (a) of 24 CFR 203.355 and the second sentence in paragraph (f) of 24 CFR 203.402, which otherwise would have become applicable on March 1, 1997. This suspension is being issued to permit HUD to consider fully the public comments on these provisions before making them applicable. The suspended provisions relate to loss mitigation procedures for single family mortgage insurance.

DATES: Effective February 28, 1997, the last sentence of the introductory test of 24 CFR 203.355(a) and the second sentence of 24 CFR 203.402(f) are suspended.

FOR FURTHER INFORMATION CONTACT: Joseph McCloskey, Director, Single Family Servicing Division, Room 9178, Department of Housing and Urban Development, 451 7th Street, SW., Washington, DC 20410, (202) 708–1672, or, TTY for hearing and speech impaired, (202) 708–4594. (These are not toll-free numbers).

SUPPLEMENTARY INFORMATION: In an interim rule published on July 3, 1996 (61 FR 35014) to implement loss mitigation procedures under section 407 of The Balanced Budget Downpayment Act, I (Pub. L. 104–99, approved January 26, 1996) (Downpayment Act), delayed implementation dates were included for provisions in two sections so that HUD would be able to consider and address any public comments on these provisions before the prescribed implementation date. The reduction from nine to six months for taking action upon default of a mortgage in § 203.355(a), and the amendment to § 203.402(f) to permit varying the percentage of foreclosure costs or the costs of acquiring a property that are reimbursed, were made to apply only after March 1, 1997.

HUD has determined that it is appropriate to delay the implementation of these provisions until the publication of a final rule. Section 203.355(a) provides, in part, that ''where the date of default is on or after March 1, 1997, the mortgagee shall take one of the following actions within six months of the date of default or within such additional time approved by HUD[.]'' Section 203.402(f) provides, in part, that: ''For mortgages insured on or after March 1, 1997, the Secretary will reimburse a percentage of foreclosure costs or costs of acquiring the property, which percentage shall be determined in accordance with such conditions as the Secretary shall prescribe.''

Accordingly, HUD is providing notice that is suspending the provision contained in the last sentence of the introductory text of paragraph (a) of § 203.355 that reduces the foreclosure initiation time frame from nine months to six months for mortgages where the default date is on or after March 1, 1997. This will leave in place the nine-month time frame in effect prior to the July 3, 1996 interim rule until HUD issues a final rule.

In addition, HUD is providing notice that it is suspending the provision contained in the second sentence of § 203.402(f) that permits HUD to vary the percentage of foreclose costs or costs of acquiring the property otherwise reimbursed for mortgages insured on or after March 1, 1997. Under this suspension, HUD will continue to reimburse foreclosure costs or costs of acquiring the property otherwise (including costs of acquiring the property by the mortgagee and of conveying and evidencing title to the property to HUD, but not including any costs borne by the mortgagee to correct title defects) actually paid by the mortgagee and approved by HUD, in an amount not in excess of two-thirds of such costs or $75, whichever is the greater. This will leave in place the reimbursement rate in effect prior to the July 3, 1996 interim rule until HUD issues a final rule.

Dated: February 28, 1997.

Nicolas P. Retsinas,

Assistant Secretary for Housing-Federal Housing Commissioner.

[FR Doc. 97–5457 Filed 2–28–97; 3:55 pm]

BILLING CODE 4210–27–M

NATIONAL LABOR RELATIONS BOARD

29 CFR Part 102

Issuance and Service of Subpoenas

AGENCY: National Labor Relations Board.

ACTION: Final rule.

SUMMARY: The Board is amending its rules to provide that the Executive Secretary may sign and issue subpoenas on behalf of the Board or any Member thereof and that the date of service of the subpoena for purposes of computing the 5-day period for filing a petition to revoke shall be construed as the date the subpoena is received.

EFFECTIVE DATE: March 5, 1997.

FOR FURTHER INFORMATION CONTACT: John J. Toner, Executive Secretary, National Labor Relations Board, 1099 14th Street, NW, Room 11600, Washington, DC 20570. Telephone: (202) 273–1940.

SUPPLEMENTARY INFORMATION: For approximately the last three years, the NLRB has been conducting an intensive internal review of its procedures at all levels of the Agency. The purpose of this internal review has been to find ways to maintain and improve the Agency's case-processing efficiency in light of the Agency's diminishing resources. Many initiatives have already been implemented by the Board as part of this ongoing review, such as the initiative authorizing the use of settlement judges and providing judges with the discretion to dispense with briefs and to issue bench decisions,